Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903291 · ClinicalTrials.gov registry record
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 333
- Enrollment target
NCT01903291: Completed study, sponsored by Biogen.
NCT01903291 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 333 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01903291 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 333 participants
- Enrollment target
Study Summary
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary objectives of this study in this study population are to assess the impact of DMF over a 12-month period on patient-reported outcomes (PROs) and health economic-related outcomes and to evaluate additional clinical outcomes at Month 12.
Interventions
- DRUG dimethyl fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-02 |
What the finished NCT01903291 record still lists
NCT01903291 is an observational study that tracks outcomes without assigning an intervention. The registered 333 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which dimethyl fumarate is the first listed.
NCT01903291 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01903291 about?
NCT01903291 is a clinical study titled "Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS". The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary objectives of this s...
What is the current status of trial NCT01903291?
This trial is currently completed. The enrollment target is 333 participants. The study started on 2013-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01903291?
The interventions under investigation include: dimethyl fumarate (DRUG).
Who is sponsoring clinical trial NCT01903291?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07395687 · 333 participants · Phase 2
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
- NCT05131672 · 334 participants · NA
Cast or Operation for Medial Epicondyle Fracture Treatment in Children
- NCT05131685 · 334 participants · NA
Distal Radius Interventions for Fracture Treatment
- NCT05546931 · 334 participants · NA
Mobile Health Program for Rural Hypertension
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia